Abstract
1 Total body clearance and renal clearance after single intravenous doses of guanfacine were 360 ± 262 (mean ± s.d.) and 233 ± 245 ml/min, respectively, in patients with normal renal function (glomerular filtration rate (GFR) > 90 ml/min), 308 ± 274 and 34 ± 22 ml/min, respectively, in patients with moderately impaired renal function (GFR 30-10 ml/min), and 257 ± 187 and 18 ± 15 ml/min, respectively, in preuremic patients (GFR < 10 ml/min).
2 The cumulative urinary excretion up to 48 h after a single intravenous injection of guanfacine was 57.0 ± 32.0% in patients with GFR > 90 ml/min, 14.0 ± 9.0% in patients with GFR 30-10 ml/min and 7.5 ± 2.4% in preuremic patients.
3 In normal as well as impaired renal function the elimination rate constant of guanfacine was 0.05 h-1, which corresponds to an elimination half-life of 14 h, independent of renal function.
4 These results suggest that non-renal elimination of guanfacine plays an important role in patients with renal failure.
5 Intestinal absorption of guanfacine was calculated to be 59 ± 19% in patients with GFR > 90 ml/min, to 68 ± 16% in patients with GFR 30-10 ml/min, and to 73 ± 36% in preuremic patients.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bream J. B., Lauener H., Picard C. W., Scholtysik G., White T. G. Substituted phenylacetylguanidines: a new class of antihypertensive agents. Arzneimittelforschung. 1975 Oct;25(10):1477–1482. [PubMed] [Google Scholar]
- Esch I. Erste Erfahrungen mit BS 100-141, einer neuen blutdrucksenkenden Substanz. Int J Clin Pharmacol Biopharm. 1976 Sep;14(2):109–112. [PubMed] [Google Scholar]
- Kirch W., Distler A. Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):132–135. [PubMed] [Google Scholar]
- Milutinovic J., Cutler R. E., Hoover P., Meijsen B., Scribner B. H. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int. 1975 Sep;8(3):185–190. doi: 10.1038/ki.1975.98. [DOI] [PubMed] [Google Scholar]
- Rahn K. H. The influence of renal function on plasma levels, urinary excretion, metabolism, and antihypertensive effect of guanethidine (ismelin) in man. Clin Nephrol. 1973 Jan-Feb;1(1):14–23. [PubMed] [Google Scholar]
- Saameli K., Scholtysik G., Waite R. Pharmacology of BS 100-141, a centrally acting antihypertensive drug. Clin Exp Pharmacol Physiol. 1975;Suppl 2:207–212. [PubMed] [Google Scholar]
- Scholtysik G., Lauener H., Eichenberger E., Bürki H., Salzmann R., Müller-Schweinitzer E., Waite R. Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141). Arzneimittelforschung. 1975 Oct;25(10):1483–1491. [PubMed] [Google Scholar]